GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » PS Ratio
中文

Prestige Consumer Healthcare (Prestige Consumer Healthcare) PS Ratio : 3.09 (As of Apr. 24, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Prestige Consumer Healthcare PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prestige Consumer Healthcare's share price is $70.13. Prestige Consumer Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $22.66. Hence, Prestige Consumer Healthcare's PS Ratio for today is 3.09.

Warning Sign:

Prestige Consumer Healthcare Inc stock PS Ratio (=3.14) is close to 5-year high of 3.29

The historical rank and industry rank for Prestige Consumer Healthcare's PS Ratio or its related term are showing as below:

PBH' s PS Ratio Range Over the Past 10 Years
Min: 1.44   Med: 2.69   Max: 3.74
Current: 3.08

During the past 13 years, Prestige Consumer Healthcare's highest PS Ratio was 3.74. The lowest was 1.44. And the median was 2.69.

PBH's PS Ratio is ranked worse than
66.77% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 2.16 vs PBH: 3.08

Prestige Consumer Healthcare's Revenue per Sharefor the three months ended in Dec. 2023 was $5.64. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $22.66.

During the past 12 months, the average Revenue per Share Growth Rate of Prestige Consumer Healthcare was 3.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 3.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 6.70% per year.

During the past 13 years, Prestige Consumer Healthcare's highest 3-Year average Revenue per Share Growth Rate was 116.50% per year. The lowest was -14.60% per year. And the median was 10.35% per year.

Back to Basics: PS Ratio


Prestige Consumer Healthcare PS Ratio Historical Data

The historical data trend for Prestige Consumer Healthcare's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Consumer Healthcare PS Ratio Chart

Prestige Consumer Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 1.95 2.36 2.48 2.77

Prestige Consumer Healthcare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.77 2.64 2.54 2.70

Competitive Comparison of Prestige Consumer Healthcare's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Consumer Healthcare's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's PS Ratio distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's PS Ratio falls into.



Prestige Consumer Healthcare PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Prestige Consumer Healthcare's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=70.13/22.662
=3.09

Prestige Consumer Healthcare's Share Price of today is $70.13.
Prestige Consumer Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.66.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Prestige Consumer Healthcare  (NYSE:PBH) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Prestige Consumer Healthcare PS Ratio Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Traded in Other Exchanges
Address
660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Executives
Mary Beth Fritz officer: Senior VP Quality & Regulatory 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi officer: Chief Executive Officer 660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca director C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco officer: Chief Financial Officer C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail other: EVP, Marketing & Sales 660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool officer: See Remarks 2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark director C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin director
Natale S Ricciardi director C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness director PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom director 660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier director 600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo officer: Senior VP Operations 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors officer: Chief Marketing Officer 660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591